Aastrom Biosciences Stock Showing Great Potential...

Not only is Aastrom Biosciences (ASTM) involved in one of the most controversial, and thus loved by traders, areas of medicine but its company insiders have placed their money where their mouths are.

Aastrom's hopes and dreams rest on its Tissue Repair Cell (TRC) technology, which the company is developing to produce autologous (from patient's body) cells and tissue for treating various conditions. These cells, harvested from patients' own bone marrow are classified as progenitor cells, thus placing Aastrom right in the middle of the stem cell tabloids.

Currently, the company is utilizing it TRC technology in clinical trials for bone regeneration and vascularization.

Just recently, the company announced positive results with its long bone fracture phase 1/2 clinical trials.

But the science and the industry are not the only features that make Aastrom stock atractive. Back in May and June of 2006 company insiders,including the chairman and director, bought stock of the company at around $1.30 a share. The stock's price after Friday's gain is now back to that level.

So, not only is the company's science exciting, but its own directors are showing confidence that the stock's current price is a bargain.